{"id":56381,"date":"2025-07-30T08:52:03","date_gmt":"2025-07-30T08:52:03","guid":{"rendered":"https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/"},"modified":"2025-07-30T08:52:03","modified_gmt":"2025-07-30T08:52:03","slug":"un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/","title":{"rendered":"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305)"},"content":{"rendered":"<p>MARIA VANESA GUTIERREZ CALDERON &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; AMGEN SA<\/p>","protected":false},"excerpt":{"rendered":"<p>MARIA VANESA GUTIERREZ CALDERON &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; AMGEN SA<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2683],"tags":[],"class_list":["post-56381","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305) - Ibima\" \/>\n<meta property=\"og:description\" content=\"MARIA VANESA GUTIERREZ CALDERON &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; AMGEN SA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:52:03+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305)\",\"datePublished\":\"2025-07-30T08:52:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/\"},\"wordCount\":57,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-22\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/\",\"name\":\"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305) - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:52:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/en\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/","og_locale":"en_GB","og_type":"article","og_title":"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305) - Ibima","og_description":"MARIA VANESA GUTIERREZ CALDERON &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; III &#8211; AMGEN SA","og_url":"https:\/\/ibima.eu\/en\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:52:03+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305)","datePublished":"2025-07-30T08:52:03+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/"},"wordCount":57,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-22"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/","url":"https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/","name":"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:52:03+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/un-estudio-de-fase-3-abierto-multicentrico-aleatorizado-de-tarlatamab-en-combinacion-con-durvalumab-versus-solo-durvalumab-en-sujetos-con-cancer-de-pulmon-de-celulas-pequenas-en-estadio-extenso-des\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Un estudio de fase 3, abierto, multic\u00e9ntrico, aleatorizado de tarlatamab en combinaci\u00f3n con durvalumab versus solo durvalumab en sujetos con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas peque\u00f1as en estadio extenso despu\u00e9s de platino, etop\u00f3sido y durvalumab (DeLLphi-305)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/56381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=56381"}],"version-history":[{"count":0,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/56381\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=56381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=56381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=56381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}